Renovo News
-
11th December 2008A briefing for analysts and investors to discuss today's clinical results and Renovo's preliminary results for the year ended 30 September 2008 (see separate announcement also issued today) will be...read more
-
28th August 2008JUVISTA® PHASE 2 TRIAL IN SCAR REVISION SURGERY COMPLETED AND OVERALL MET ITS PRIMARY ENDPOINT. AGREED JOINT DEVELOPMENT PLAN FOR JUVISTA® WITH SHIRE<...read more
-
25th July 2008Renovo Group plc (LSE: RNVO), the biopharmaceutical company developing drugs for the reduction of scarring and acceleration of healing, today announces that effective from 1 August 2008 Mr David Bl...read more
-
10th July 2008Renovo Group plc (LSE: RNVO), the biopharmaceutical company developing drugs for the reduction of scarring and acceleration of healing, is pleased to announce that it has received positive feedback...read more
-
29th May 2008Renovo Group plc (LSE: RNVO), the biopharmaceutical company developing drugs for the reduction of scarring and acceleration of healing, today received notification (subsequent to the release of t...read more
-
17th April 2008Renovo Group plc (LSE: RNVO), the biopharmaceutical company developing drugs for the reduction of scarring, today announces positive results of the planned 12 month follow-up analysis of two Juvi...read more
-
3rd April 2008Renovo is pleased to announce that Dr Sharon O'Kane, CSO, was named as the Entrepeneur of the Year at the inaugural Northwest Women in Business Awards in Merseyside last week....read more